Director of the Rheumatology Unit/Senior Lecturer, Pediatrics, Tel Aviv University; Schneider Children’s Medical Center Dr. Gil Amarilyo is an Associate Professor in the Department of Pediatrics at the Gray Faculty […]
Professor, Department of Medicine, NYU Grossman School of Medicine / NYU Langone Health Professor, Department of Pathology, NYU Grossman School of Medicine / NYU Langone Health Co-Director, Division of Precision […]
Using wearable sensors and machine learning to analyze real-world movement and sleep data, this project aims to predict treatment response earlier and enable more personalized care for inflammatory arthritis.
Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Developing a bioavailable DNAseIL3 biologic to degrade pathogenic autoantibodies and treat lupus and related autoimmune diseases.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
A Colton-supported NYU study published in Science Immunology has discovered that the immune checkpoint protein PD-1 functions as a dimer — a finding that could transform drug design for both cancer and autoimmune disease.
Penn Medicine's Colton Center is leading a new wave of precision immunotherapy for autoimmune disease — from CAAR T cell therapy for pemphigus to immune profiling tools that could one day cure these conditions.
Penn Medicine's new Colton Center for Autoimmunity unites the university's immunology research and patient care programs, joining NYU and Yale in a shared effort to advance autoimmune disease diagnosis and treatment.
